“`html
BioNxt Solutions (OTCQB:BNXTF) has completed a debt settlement transaction with an arm’s length creditor. The company settled a total debt of $225,010 through a combination of share issuance and cash payment. The settlement included issuing 112,505 common shares at CAD$1.00 per share and making a cash payment of $112,505.
The issued shares are subject to a mandatory four-month and one-day holding period in compliance with CSE policies and Canadian securities regulations.
BioNxt Solutions (OTCQB:BNXTF) ha completato una transazione di sistemazione del debito con un creditore indipendente. L’azienda ha estinto un debito totale di 225.010 USD mediante una combinazione di emissione di azioni e pagamento in contanti. L’accordo prevedeva l’emissione di 112.505 azioni ordinarie al prezzo di CAD$1,00 per azione e un pagamento in contanti di 112.505 USD. Le azioni emesse sono soggette a un periodo di detenzione obbligatorio di quattro mesi e un giorno, in conformità alle politiche CSE e alle normative sui titoli canadesi.
BioNxt Solutions (OTCQB:BNXTF) ha completado una transacción de liquidación de deuda con un acreedor independiente. La empresa liquidó una deuda total de 225.010 USD mediante una combinación de emisión de acciones y pago en efectivo. La liquidación incluyó la emisión de 112.505 acciones ordinarias a un precio de CAD$1,00 por acción y un pago en efectivo de 112.505 USD. Las acciones emitidas están sujetas a un período de tenencia obligatorio de cuatro meses y un día, de conformidad con las políticas de la CSE y la normativa de valores canadiense.
BioNxt Solutions (OTCQB:BNXTF)가 독립 채권자와의 부채 조정 거래를 완료했습니다. 회사는 주식 발행과 현금 지급의 조합을 통해 총 225,010 USD의 부채를 상환했습니다. 조정에는 주당 CAD$1.00에 발행된 112,505주 보통주와 현금 112,505 USD의 지급이 포함됩니다. 발행된 주식은 CSE 정책 및 캐나다 증권 규정을 준수하여 4개월 1일의 의무 보유 기간의 적용을 받습니다.
BioNxt Solutions (OTCQB: BNXTF) a finalisé une opération de règlement de dettes avec un créancier indépendant. La société a réglé une dette totale de 225 010 USD par une combinaison d’émission d’actions et de paiement en espèces. L’accord prévoyait l’émission de 112 505 actions ordinaires à un prix de CAD$1,00 par action et un paiement en espèces de 112 505 USD. Les actions émises sont soumises à une période de détention obligatoire de quatre mois et un jour, conformément aux politiques de la CSE et à la réglementation canadienne sur les valeurs mobilières.
BioNxt Solutions (OTCQB:BNXTF) hat eine Schuldenbereinigungsvereinbarung mit einem unabhängigen Gläubiger abgeschlossen. Das Unternehmen hat eine Gesamtsumme von 225.010 USD durch eine Kombination aus Aktienausgabe und Barzahlung beglichen. Die Abrechnung sah die Ausgabe von 112.505 Stammaktien zu CAD$1,00 pro Aktie sowie eine Barzahlung von 112.505 USD vor. Die ausgegebenen Aktien unterliegen gemäß den Richtlinien der CSE und den kanadischen Wertpapiergesetzen einer zwingenden Haltefrist von vier Monaten und einem Tag.
BioNxt Solutions (OTCQB:BNXTF) أنهت صفقة تسوية ديون مع دائن مستقل. قامت الشركة بتسوية إجمالي دين قدره 225,010 دولارًا أمريكيًا من خلال مزيج من إصدار أسهم ودفع نقدي. شملت التسوية إصدار 112,505 سهم عادي بسعر CAD$1.00 للسهم ودفعًا نقديًا قدره 112,505 دولار. الأسهم الصادرة خاضعة لفترة حيازة إلزامية مدتها أربعة أشهر ويوم واحد، وفق سياسات CSE والتنظيمات الكندية للأوراق المالية.
BioNxt Solutions (OTCQB:BNXTF) 已与独立债权人完成债务和解交易。公司通过发行股票和现金支付的组合方式，清偿总额为225,010 USD的债务。和解包括按每股CAD$1.00发行112,505股普通股，以及支付现金112,505 USD。发行的股票需遵循加拿大证券交易所的政策及加拿大证券法规，设有强制性四个月零一天的持有期。
Positive
- Debt reduction of $225,010 through partial equity conversion
- Preservation of cash through 50% equity settlement of debt
Negative
- Dilution of existing shareholders through issuance of 112,505 new shares
09/19/2025 – 09:45 PM
VANCOUVER, BC – September 19, 2025 – BioNxt Solutions Inc. (CSE:BNXT)(OTCQB:BNXTF)(FSE:4XT) announced today the completion of a debt settlement agreement, initially disclosed on September 12, 2025, with an independent creditor. The agreement resolves an outstanding debt of $225,010 owed for services previously rendered to the company.
Under the terms of the settlement, BioNxt issued 112,505 common shares at a price of CAD$1.00 per share while also making a cash payment of $112,505 to the creditor. This strategic combination of equity and cash aims to optimize the company’s capital structure and reduce its financial obligations.
The newly issued shares are subject to a standard four-month and one-day hold period, as mandated by the Canadian Securities Exchange (“CSE”) regulations and applicable Canadian securities laws. This holding period is a common practice to prevent immediate resale and potential market volatility.
From a financial perspective, this debt settlement offers BioNxt Solutions a dual advantage. By settling half of the debt through equity, the company conserves crucial cash reserves, allowing for continued investment in its core business operations, particularly in R&D and upcoming regulatory approval processes. However, analysts note that while the cash preservation is beneficial, the issuance of new shares could result in a minor dilution of value for existing shareholders. The market response will largely depend on how BioNxt leverages the freed-up cash to drive future growth and value creation.
BioNxt’s core focus revolves around bioscience innovation, with a particular emphasis on next-generation drug delivery technologies. Their proprietary platforms—including Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)—target significant therapeutic areas such as autoimmune diseases, neurological disorders, and solutions aimed at promoting longevity. Positioned with R&D operations spanning North America and Europe, BioNxt is strategically pursuing regulatory approvals and subsequent commercialization, prioritizing the European markets for initial launch.
“This debt settlement is a calculated step towards strengthening our financial footing as we advance our innovative drug delivery systems,” stated a company spokesperson. “The balanced approach of share issuance and cash payment allows us to manage our debt effectively while preserving capital for critical development initiatives.”
Investors and industry observers will be closely monitoring BioNxt’s progress as it navigates the regulatory landscape and prepares for the commercial rollout of its innovative platforms, especially within the high-potential European market. Success in these endeavors will ultimately determine the long-term impact of this debt settlement on shareholder value.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTCQB Markets:BNXTF and trades in Germany under WKN:A3D1K3.
FAQ
What is the value of BioNxt Solutions’ (BNXTF) recent debt settlement?
BioNxt Solutions settled a total debt of $225,010, with half paid in shares and half in cash.
How many shares did BioNxt Solutions (BNXTF) issue for the debt settlement?
BioNxt Solutions issued 112,505 common shares at a deemed price of CAD$1.00 per share.
What is the lock-up period for the shares issued in BioNxt’s debt settlement?
The shares are subject to a four-month and one-day statutory hold period in accordance with CSE policies and Canadian securities laws.
How did BioNxt Solutions (BNXTF) structure the debt settlement payment?
The settlement was structured as a 50/50 split: $112,505 in shares and $112,505 in cash.
“`
Original article, Author: Jam. If you wish to reprint this article, please indicate the source:https://aicnbc.com/9659.html
